contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-secures-availability-its-home-tests-strategic-partnership-and-minority

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.

Nightingale Health

On Tuesday June 29, Nightingale announced it has renewed its agreement with and made a strategic investment in the healthcare technology company Weavr Health (former Boston MicroFluidics).

Translation: Original comment published in Finnish on 06/29/2021 at 14:23 On Tuesday June 29, Nightingale <a href="https://www.inderes.fi/en/tiedotteet/nightingale-health-nightingale-secures-global-scalability-its-home-solution-partnering">announced</a> it has renewed its agreement with and made a strategic investment in the healthcare technology company Weavr Health (former Boston MicroFluidics). Weavr is the manufacturer of the Velvet™ device, which Nightingale uses in its at-home pilot launched in the second quarter of 2021. The agreed strategic partnership enables global scalability of Nightingale's at-home testing solution and Nightingale announced it will launch its commercial at-home testing offering directly to consumers and to partners in the first half of 2022. As a part of the strategic partnership and renewed commercial terms, Nightingale invested around EUR 3.5 million to Weavr in the form of a convertible loan. This partnership and agreement help Nightingale secure the long-term availability of Weavr’s technology by agreeing on usage rights to Weavr’s intellectual properties, so we believe the company now has clear preconditions to expand at-home testing. According to the release, the samples remain stable for up to 28 days at room temperature, which we believe enables serving an expansive geographical area without having to invest in new local laboratories. Last week, Nightingale reported on the progress of its at-home test and we commented on the news <a href="https://www.inderes.fi/en/uutiset/nightingales-home-blood-testing-pilot-attracted-interest-and-advancing-track">here</a>.

Inderes

Nightingale secures availability of its at-home tests with a strategic partnership and minority investment in Weavr Health

	2020	21e	22e
Revenue	1.6	2.0	2.4
growth-%	-22.9 %	28.3 %	18.5 %
EBIT (adj.)	-3.4	-2.5	-6.9
EBIT-% (adj.)	-214.5 %	-121.5 %	-287.7 %
EPS (adj.)	0.00	-0.05	-0.12
Dividend	0.00	0.00	0.00
Dividend %		0.0 %	0.0 %
P/E (adj.)	-	neg.	neg.
EV/EBITDA	-	neg.	neg.

Nightingale secures availability of its at-home tests with a strategic partnership and minority investment in Weavr Health

Nightingale Health

Key Estimate Figures19.04.2021

Privacy preferences